scholarly journals Sodium-Dependent Noradrenaline Transporter

2020 ◽  
Author(s):  
Keyword(s):  
Noradrenaline Transporter ◽  
Sodium Dependent

A Case of Congenital Glucose Galactose Malabsorption with a New Mutation in the SLC5A1 Gene

2020 ◽  
Author(s):  
Hasan Akduman ◽  
Dilek Dilli ◽  
Serdar Ceylaner
Keyword(s):  
Mutation Analysis ◽  
Autosomal Recessive ◽  
Glucose Transporter ◽  
Neonatal Period ◽  
Autosomal Recessive Disorder ◽  
Homozygous Mutation ◽  
New Mutation ◽  
Early Neonatal Period ◽  
Sodium Dependent ◽  
Hypernatremic Dehydration

AbstractCongenital glucose-galactose malabsorption (CGGM) is an autosomal recessive disorder originating from an abnormal transporter mechanism in the intestines. It was sourced from a mutation in the SLC5A1 gene, which encodes a sodium-dependent glucose transporter. Here we report a 2-day-old girl with CGGM who presented with severe hypernatremic dehydration due to diarrhea beginning in the first hours of life. Mutation analysis revealed a novel homozygous mutation NM_000343.3 c.127G > A (p.Gly43Arg) in the SLC5A1 gene. Since CGGM can cause fatal diarrhea in the early neonatal period, timely diagnosis of the disease seems to be essential.

Type 1 Sodium-Dependent Phosphate Transporter acts as a Membrane Potential-Driven Urate Exporter

2013 ◽  
Vol 6 (2) ◽  
pp. 88-94 ◽  
Author(s):  
Takaaki Miyaji ◽  
Tatsuya Kawasaki ◽  
Natsuko Togawa ◽  
Hiroshi Omote ◽  
Yoshinori Moriyama
Keyword(s):  
Membrane Potential ◽  
Phosphate Transporter ◽  
Sodium Dependent

Effect of calcium on transport characteristics of cultured proximal renal cells

1985 ◽  
Vol 249 (3) ◽  
pp. F346-F355
Author(s):  
L. M. Sakhrani ◽  
N. Tessitore ◽  
S. G. Massry
Keyword(s):  
Phosphate Uptake ◽  
Cytosolic Calcium ◽  
Ruthenium Red ◽  
Extracellular Calcium ◽  
Transport Processes ◽  
Renal Cells ◽  
Sodium Uptake ◽  
Calcium Loading ◽  
Sodium Dependent ◽  
Acute Changes

We examined the effects of acute changes in extracellular and intracellular calcium on transport processes in primary culture of proximal rabbit renal cells. A change in extracellular calcium from 0 to 3 mM inhibited amiloride-sensitive sodium uptake by 30%, and this effect was maximal at 1 mM calcium. Other polyvalent cations (Mn2+, Mg2+, La3+, and Ba2+) produced quantitatively similar inhibition of amiloride-sensitive sodium uptake compared with calcium. An increase in cytosolic calcium produced by calcium loading (20 mM) or by A23187 (20 microM) resulted in an inhibition of 25-40% of amiloride-sensitive sodium uptake. Moreover, quinidine (10(-4)M) and ruthenium red (3 microM), agents presumed to increase cytosolic calcium, inhibited amiloride-sensitive sodium uptake by 20-60%. Both these agents also inhibited sodium-dependent phosphate uptake by 20% but had no effect on ouabain-sensitive 86Rb+ uptake or on sodium-dependent alpha-methylglucoside uptake. Our data indicate that increases in extracellular calcium inhibit amiloride-sensitive sodium uptake and increases in cytosolic calcium inhibit sodium-dependent phosphate and amiloride-sensitive sodium uptakes. The effect of extracellular calcium may be due to charge screening and/or binding to the negatively charged plasma membrane or due to alterations in membrane fluidity.

Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors

2019 ◽  
Vol 83 ◽  
pp. 520-525 ◽  
Author(s):  
Kuang-Feng Chu ◽  
Jen-Shin Song ◽  
Chiung-Tong Chen ◽  
Teng-Kuang Yeh ◽  
Tsung-Chih Hsieh ◽  
...  
Keyword(s):  
Biological Evaluation ◽  
Indole Derivatives ◽  
Sodium Dependent ◽  
Synthesis And Biological Evaluation

scholarly journals Gliflozine – in Zukunft Kardioprotektiva?

Der Internist ◽  
2021 ◽  
Author(s):  
Ursula Rauch-Kröhnert ◽  
Ulf Landmesser
Keyword(s):  
Diabetes Mellitus ◽  
Sglt2 Inhibitor ◽  
Diabetes Mellitus Typ 2 ◽  
Sodium Dependent

ZusammenfassungGliflozine (Inhibitoren der „sodium-dependent glucose cotransporter“, SGLT) sind Arzneistoffe, die ursprünglich zur Behandlung des Diabetes mellitus eingesetzt und der Gruppe der Antidiabetika zugeordnet wurden. Seit November 2020 ist mit Dapagliflozin erstmalig ein SGLT2-Inhibitor zur Behandlung von Patienten mit Herzinsuffizienz (mit reduzierter linksventrikulärer Funktion), unabhängig vom Diabetesstatus, zugelassen worden. Das Präparat Empagliflozin hat gerade – im Juni 2021 – von der europäischen Arzneimittelbehörde (EMA) eine Zulassung für die Therapie der Herzinsuffizienz mit reduzierter Ejektionsfraktion erhalten. Somit stehen verschiedene Gliflozine nicht nur zur Behandlung des Diabetes mellitus, sondern auch der Herzinsuffizienz zur Verfügung. Der vorliegende Beitrag vermittelt Grundlagenkenntnisse zu den Gliflozinen und bietet eine Übersicht zur ihrer Bedeutung sowohl in der Behandlung des Diabetes mellitus Typ 2 als auch aufgrund ihrer kardio- und nephroprotektiven Funktion.

Sign in / Sign up

Export Citation Format

Share Document